TheEdgeResearch
Home / Stocks / SLGL

Sol-Gel Technologies Ltd. (SLGL)

NASDAQ Healthcare Biotechnology
$55.17 ▲ +2.02%
Market Cap
$180.6M
Sector
Healthcare
Industry
Biotechnology
Beta
1.24
52-Wk Range
34.47-97.97
CEO
Moshe Arkin
Country
IL
Currency
USD

Sol-Gel Technologies Ltd. operates in the Biotechnology industry of the Healthcare sector, headquartered in Ness Ziona, TA, IL. The stock last traded at $55.17, up 2.02% on the session, giving a market capitalisation of $180.6M. On trailing twelve-month figures it carries a trailing P/E of -10.55, a net margin of -1115.4%. Its beta of 1.24 implies it has historically moved more than the broad market.

Valuation & profitability (TTM)
P/E
-10.55
Price / Sales
125.78
Price / Book
4.22
EV / EBITDA
-9.87
Gross margin
100.0%
Operating margin
-1221.0%
Net margin
-1115.4%
Return on equity
—
Debt / equity
0.02
Current ratio
7.12
Dividend yield
0.0%
Payout ratio
0.0%
Company profile
Exchange
NASDAQ Global Market
Employees
28
IPO date
2018-02-01
Headquarters
Ness Ziona, TA, IL
About Sol-Gel Technologies Ltd.

Sol-Gel Technologies Ltd., a pharmaceutical firm currently in its clinical development phase, specializes in the creation and market introduction of skin-applied medications. These products leverage the company's distinctive microencapsulation technology, with their primary development and commercialization activities centered in Israel. Sol-Gel's pipeline features several key candidates. Twyneo, an innovative, non-antibiotic topical cream designed for once-daily application, has successfully concluded Phase III trials for treating acne vulgaris. Similarly, Epsolay, another topical cream administered once a day, has also completed its Phase III studies, targeting papulopustular rosacea. Advancing through Phase I clinical trials is SGT-210, intended for palmoplantar keratoderma. Furthermore, the company is investigating Erlotinib, Tapinarof, and Roflumilast as potential treatments for psoriasis and various other medical conditions. Beyond its proprietary offerings, the company also engages in creating generic versions of topical dermatological medications. Sol-Gel Technologies maintains a strategic partnership with Perrigo. Established in 1997, the company maintains its headquarters in Ness Ziona, Israel.

Comparable companies

Sol-Gel Technologies Ltd. is most often compared with the following Healthcare names:

ANEBCLNNCOYAMGNXOKYOORMPOVIDPLRXTLSAZNTL
More research on SLGL
SLGL technical analysis SLGL TheEdge Score Compare against peers
Open full interactive analysis & DCF →